Trial Profile
An Extension Study of Venetoclax in Subjects With Advanced Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2019
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors AbbVie
- 18 Dec 2019 Status changed from active, no longer recruiting to completed.
- 05 Oct 2018 Planned End Date changed from 1 Dec 2018 to 19 Jun 2019.
- 12 Sep 2018 Planned End Date changed from 2 Oct 2018 to 1 Dec 2018.